# V1 Empirics Check — mistralai/mistral-large-2512 (Variant B)

**Model:** mistralai/mistral-large-2512
**Variant:** B
**Date:** 2026-03-25T15:09:13.306990

---

### 1. Idea Fidelity

The paper largely adheres to the original idea manifest but deviates in several important ways:

**Strengths:**
- The core research question (effect of the EU Trade Secrets Directive on business R&D) and identification strategy (staggered DiD at NUTS2 level) are faithfully executed.
- The use of the Callaway-Sant’Anna estimator for staggered adoption is appropriate and well-justified.
- The treatment heterogeneity analysis (pre-existing legal protection strength) aligns with the manifest’s emphasis on "heterogeneous treatment intensity."

**Deviations:**
- **Sample size:** The manifest promised 431 NUTS2 regions (3,251 observations), but the paper uses only 83 regions (1,162 observations) in a balanced panel. This is a major reduction, likely due to data availability, but it weakens the original claim of "431 NUTS2 regions" and reduces statistical power.
- **Time window:** The manifest proposed 4 pre-treatment years (2014–2017) and up to 6 post-treatment years (2019–2024). The paper uses 8 pre-treatment years (2010–2017) but only 5 post-treatment years (2019–2023), which is reasonable but narrower than promised.
- **Secondary outcomes:** The manifest listed manufacturing value added, high-tech exports, firm births, and ECB lending rates as secondary outcomes, but these are not analyzed in the paper. This is a notable omission, as they could provide complementary evidence on the Directive’s broader economic effects.
- **Never-treated group:** The manifest did not mention excluding countries with pre-existing laws (e.g., Czechia, Hungary), but the paper classifies them as "never-treated." This is defensible but should be justified more explicitly.

**Conclusion:** The paper pursues the original idea but with significant scope reductions (sample size, outcomes) that limit its contribution relative to the manifest’s ambitions.

---

### 2. Summary

This paper exploits the staggered transposition of the EU Trade Secrets Directive (2016/943) to estimate its causal effect on business R&D expenditure (BERD) across 83 NUTS2 regions. Using a Callaway-Sant’Anna staggered difference-in-differences design, the authors find a precisely estimated null effect: the Directive did not measurably increase BERD intensity. The null is robust to alternative estimators, clustering, and leave-one-country-out analysis, though a suggestive (but insignificant) gradient emerges where countries with weaker pre-existing protection show larger positive effects. The paper contributes to the literature on trade secrets and innovation policy by providing the first causal evidence on the EU Directive’s effects.

---

### 3. Essential Points

**Critical Issue 1: Sample Size and Power**
- The manifest promised 431 NUTS2 regions, but the paper uses only 83. This raises concerns about statistical power and generalizability.
  - *Action:* The authors must justify the sample reduction (e.g., data availability, missingness patterns) and explicitly acknowledge the trade-off between balance and sample size. They should also report power calculations for the reduced sample to confirm the null is not due to low power. If the full unbalanced panel (229 regions) is used in robustness checks, this should be the primary specification.

**Critical Issue 2: Parallel Trends Assumption**
- The event study shows noisy pre-trends at longer horizons (e.g., -8 and -9 years), which could reflect differential trends unrelated to the Directive.
  - *Action:* The authors should:
    1. Focus the event study on the 4–5 years immediately pre-treatment (as promised in the manifest) to align with the parallel trends assumption.
    2. Test for differential pre-trends using the method in *Roth (2022)* or *Bilinski and Hatfield (2020)*.
    3. Report placebo tests for alternative "treatment" dates (e.g., 2015, 2016) to rule out spurious trends.

**Critical Issue 3: Treatment Heterogeneity and Interpretation**
- The heterogeneity analysis (Table 4) shows a monotonic gradient, but the coefficients are insignificant and the "high protection" group’s negative point estimate (-0.238) is implausibly large (64% of a standard deviation).
  - *Action:* The authors must:
    1. Clarify whether the "high protection" group’s estimate is driven by outliers (e.g., Germany or France) and report leave-one-region-out robustness.
    2. Avoid overinterpreting the gradient as evidence of a "real if modest effect" without statistical significance. The discussion should emphasize that the heterogeneity is suggestive but inconclusive.

---

### 4. Suggestions

#### **Conceptual and Theoretical Improvements**
1. **Mechanism Clarity:**
   - The paper argues that firms may rely on private substitutes (e.g., NDAs, non-competes) rather than statutory protection, but it does not test this directly. Suggestions:
     - Use firm-level data (e.g., Community Innovation Survey) to test whether firms with stronger internal secrecy measures respond less to the Directive.
     - Add a theoretical model or framework (e.g., a simple decision tree for firms choosing between patents and secrecy) to guide the empirical analysis.

2. **Broader Literature:**
   - The paper cites *Arora et al. (2014)* and *Arrow (1962)* but does not engage with recent work on trade secrets and innovation, such as:
     - *Graham et al. (2021, JEMS)* on the DTSA’s effects in the U.S.
     - *Williams (2017, AER)* on the role of secrecy in pharmaceutical innovation.
     - *Galasso and Schankerman (2018, RESTUD)* on patent thickets and secrecy.
   - *Action:* Expand the literature review to situate the paper in the broader debate on IP regimes and innovation.

3. **Policy Implications:**
   - The conclusion that "legal harmonization changed the law but not the investment" is provocative but could be sharpened. Suggestions:
     - Discuss whether the null result implies that the Directive was unnecessary or whether it achieved other goals (e.g., reducing litigation costs, improving cross-border enforcement).
     - Compare the EU’s harmonization approach to other IP reforms (e.g., the U.S. DTSA) to highlight what might explain the null.

#### **Empirical Improvements**
4. **Data and Sample:**
   - The manifest promised 431 regions, but the paper uses 83. While the balanced panel is cleaner, the authors should:
     - Report results for the full unbalanced panel (229 regions) as the primary specification, with the balanced panel as a robustness check.
     - Explain why BERD data is missing for so many regions (e.g., biennial reporting, confidentiality) and whether missingness is random.
     - Consider imputation or inverse probability weighting to address missingness.

5. **Secondary Outcomes:**
   - The manifest listed manufacturing value added, high-tech exports, firm births, and lending rates as secondary outcomes. These are not analyzed in the paper.
     - *Action:* Add a table or appendix with results for these outcomes, even if null. They could provide complementary evidence (e.g., if the Directive increased high-tech exports but not BERD, it might suggest a shift in innovation strategy).

6. **Heterogeneity Analysis:**
   - The heterogeneity by pre-existing protection strength is a strength, but the analysis could be refined:
     - Use the continuous *Baker McKenzie (2016)* survey scores instead of discrete tiers to avoid arbitrary cutoffs.
     - Test for heterogeneity by industry (e.g., high-tech vs. low-tech) or firm size (using SBS data), as the Directive’s effects may vary across sectors.
     - Report results for the "never-treated" group (Czechia, Hungary, etc.) separately to confirm they are indeed unaffected.

7. **Robustness Checks:**
   - The robustness checks are thorough but could be expanded:
     - **Dynamic Effects:** The event study shows post-treatment coefficients at +0 and +1, but the manifest promised up to 6 post-treatment years. Extend the event study to +5 years to test for delayed effects.
     - **Alternative Estimators:** The paper uses Callaway-Sant’Anna, TWFE, and Sun-Abraham, but could also include:
       - *de Chaisemartin and D’Haultfœuille (2020)*’s estimator for staggered DiD.
       - *Borusyak et al. (2021)*’s imputation-based approach.
     - **Synthetic Controls:** For countries with the largest treatment doses (e.g., Poland, Romania), construct synthetic control units to test for effects in the most affected regions.

8. **Placebo Tests:**
   - The placebo test (column 5 of Table 3) applies treatment two years early, but this is not a true placebo (since the Directive was already adopted in 2016). Suggestions:
     - Use a "fake" Directive adoption date (e.g., 2015) for a cleaner placebo.
     - Test for differential trends in the pre-period using *Roth (2022)*’s method.

9. **Standard Errors and Clustering:**
   - The paper clusters at the country level (15 clusters), which is appropriate but may understate uncertainty. Suggestions:
     - Report *Conley (1999)* standard errors to account for spatial correlation across regions.
     - Use *Cameron et al. (2008)*’s wild cluster bootstrap for small-cluster inference.

#### **Presentation and Clarity**
10. **Tables and Figures:**
    - **Table 1 (Transposition):** Add a column for "pre-existing protection strength" (from Baker McKenzie) to make the heterogeneity more transparent.
    - **Table 2 (Summary Stats):** Include a column for the post-treatment period (2018–2023) to show trends over time.
    - **Event Study Plot:** The event study is described in text but not shown. Add a figure with 95% confidence intervals for the dynamic effects.
    - **Heterogeneity Plot:** Replace Table 4 with a plot showing the gradient across protection tiers, with confidence intervals.

11. **Discussion of Null Results:**
    - The paper does a good job interpreting the null but could address alternative explanations more explicitly:
      - **Measurement Error:** BERD is self-reported and may not capture shifts in R&D composition (e.g., from patents to secrecy).
      - **General Equilibrium Effects:** The Directive may have increased R&D in some regions while reducing it in others (e.g., via competition), leading to a null net effect.
      - **Compliance:** Firms may not have been aware of the Directive’s changes, or enforcement may have been weak. Cite evidence on awareness (e.g., surveys of EU firms).

12. **Appendix:**
    - Move the following to the appendix:
      - Detailed transposition dates (Table 1) and summary stats (Table 2).
      - Robustness checks (Table 3) and heterogeneity (Table 4).
      - Standardized effect sizes (Table A1).
    - Add an appendix with:
      - Balance tests for pre-treatment covariates (e.g., GDP, employment) across treatment cohorts.
      - Results for the never-treated group.
      - Full regression output for all specifications.

#### **Minor Suggestions**
13. **Abstract:**
    - Clarify that the null effect is for *business* R&D (not total R&D). Mention the suggestive heterogeneity gradient.
14. **Introduction:**
    - Add a sentence on why the EU setting is advantageous (e.g., "The EU’s harmonization provides a cleaner natural experiment than U.S. state-level variation, where trade secret law evolved endogenously").
15. **Institutional Background:**
    - Briefly explain why some countries (e.g., Czechia, Hungary) had pre-existing laws that met the Directive’s requirements. This helps justify their exclusion.
16. **Empirical Strategy:**
    - Clarify why the not-yet-treated group is preferred over the never-treated group (e.g., "The never-treated group is too small for reliable inference").
17. **Conclusion:**
    - Add a sentence on policy implications: "The null result suggests that further harmonization of trade secret law may not be a priority for stimulating R&D in the EU."

---

### Final Assessment
This is a well-executed paper with a compelling research design and a null result that is precisely estimated and robust. The deviations from the manifest (sample size, secondary outcomes) are the main weaknesses, but the core contribution—causal evidence on the EU Trade Secrets Directive—is novel and policy-relevant. With the suggested improvements (especially on sample size, parallel trends, and heterogeneity), the paper would make a strong contribution to *AER: Insights*. As it stands, it is a solid but not yet outstanding submission. **Revise and resubmit.**
